L
Lexeo Therapeutics, Inc. (LXEO)
NGM – Real Time Price. Currency in USD
5.70
-0.42 (-6.86%)
At close: May 12, 2026, 4:00 PM EDT
5.89
+0.19 (3.33%)
Pre-market: May 13, 2026, 4:39 AM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
5.70
-0.42 (-6.86%)
At close: May 12, 2026, 4:00 PM EDT
5.89
+0.19 (3.33%)
Pre-market: May 13, 2026, 4:39 AM EDT
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has a license agreement with Cornell University to conduct the Phase 1/2 clinical trial of LX1001, as well as support the development of the LX1004 program; a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.
| Name | Position |
|---|---|
| Dr. Eric Adler M.D. | Advisor |
| Dr. Jose Manuel Otero Ph.D. | Chief Operating Officer |
| Dr. Narinder P. Bhalla FACC, FSCAI, M.D. | Chief Medical Officer |
| Dr. Ronald G. Crystal M.D. | Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board |
| Mr. Louis Tamayo | CFO & Principal Accounting Officer |
| Mr. R. Nolan Townsend M.B.A. | CEO & Director |
| Mr. Ryan McHenry | VP & Corporate Controller |
| Ms. Leslie DiRisio | Senior Vice President of Development Operations |
| Date | Type | Document |
|---|---|---|
| 2026-05-11 | 8-K | lxeo-20260511.htm |
| 2026-04-30 | 8-K | lxeo-20260428.htm |
| 2026-03-31 | S-8 | lxeo-20260330.htm |
| 2026-03-30 | 8-K | lxeo-20260330.htm |
| 2026-03-30 | 10-K | lxeo-20251231.htm |
| 2026-02-05 | 8-K | lxeo-20260130.htm |
| 2026-01-27 | 8-K | lxeo-20260127.htm |
| 2026-01-12 | 8-K | lxeo-20260112.htm |
| 2025-11-25 | CORRESP | filename1.htm |
| 2025-11-05 | S-8 | lxeo-20251105.htm |